Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Giessen – page 13

248 clinical trials in Giessen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Giessen at a glance
248
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

248 trials in Giessen

Open in trial search

Pulmonary arterial hypertension

Not recruiting

Long-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Immune Response and Safety of RSVPreF3 Vaccine in Adults 18+ with Lung or Kidney Transplants at Risk of RSV Infections, Compared to Healthy Adults 50+

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Pulmonary hypertension

Not recruiting

Study on Sotatercept for Treating Pulmonary Hypertension in Patients with Heart Failure with Preserved Ejection Fraction

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effects of PF-07868489 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:PF-07868489
  • Sponsor:Pfizer Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Safety and Effectiveness of Taladegib for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Taladegib
  • Sponsor:Endeavor Biomedicines Inc.

Mucopolysaccharidosis II

Not recruiting

Study on the Effects and Safety of JR-141 and Idursulfase for Patients with Hunter Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Idursulfase
  • Sponsor:Jcr Pharmaceuticals Co. Ltd.

Neoplasm+1

Not recruiting

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:VERT-002
  • Sponsor:Pierre Fabre Medicament

Pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Study on Higher Doses of Nusinersen for Patients with Spinal Muscular Atrophy Who Previously Participated in a Nusinersen Study

Not recruiting
InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Pulmonary hypertension

Not recruiting

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Relapsing multiple sclerosis

Not recruiting

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Fenebrutinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Giessen

What the registry says about research in the country

01 Respiratory Disease Research

Innovative trials focusing on pulmonary hypertension and lung cancer treatments, including evaluation of novel therapies for various stages of NSCLC and rare pulmonary conditions.

  • Pulmonary Arterial Hypertension
  • Non-Small Cell Lung Cancer
  • Idiopathic Pulmonary Fibrosis

Multiple studies are investigating targeted therapies and combination treatments for advanced lung diseases.

02 Rare Disease Studies

Comprehensive research into rare genetic conditions, including Leber congenital amaurosis and Niemann-Pick disease, with trials testing innovative therapeutic approaches.

  • Ataxia Telangiectasia
  • Spinal Muscular Atrophy
  • Hunter Syndrome

These studies aim to improve treatment options for patients with rare genetic disorders.

03 Oncology Research

Advanced clinical trials examining new treatments for various cancers, particularly focusing on head and neck cancer and innovative immunotherapy combinations.

  • Metastatic Lung Cancer
  • Ovarian Cancer
  • Squamous Cell Carcinoma

Studies are evaluating novel drug combinations and targeted therapies for better treatment outcomes.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.